Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Lowers the risk of sexually acquired HIV-1 infection. Sold as Apretude. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Cabotegravir (sold as Apretude), first approved Dec 20, 2021, with 1 new use approved and 0 published complete response letters.
First approved: Dec 20, 2021
Applications: 1
New uses approved: 1
Complete response letters: 0
Medicare spending, 2025: $13.3M
First approved in the EU: Dec 17, 2020
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
APRETUDE
Part B
$13.3M
New
858
Apretude
Part D
$0K
-100%
0
Approvals in the EU (EMA)
First approved in the EU 12 months before the US. Centrally authorised medicines, matched by ingredient; see all EU approvals
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
